Quarterly report pursuant to Section 13 or 15(d)

Cancer Genetics, Inc. Merger (Details Narrative)

v3.21.1
Cancer Genetics, Inc. Merger (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 30, 2021
Aug. 21, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Aug. 21, 2021
Feb. 23, 2021
Business Acquisition [Line Items]              
Common Stock, Par or Stated Value Per Share     $ 0.0001   $ 0.0001    
Business combination acquisition related costs     $ 2,145,000      
Business combination accounts payable           $ 3,258,000  
Business combination intangible assets           $ 9,500,000  
Common Stock [Member]              
Business Acquisition [Line Items]              
Stock issued during the period for merger, shares     11,007,000        
Merger Agreement [Member] | Investor [Member]              
Business Acquisition [Line Items]              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights             143,890
Merger Agreement [Member] | StemoniX [Member]              
Business Acquisition [Line Items]              
Stock issued during the period for merger, shares 804,711,000            
Business combination consideration amount $ 59,900,000            
Merger Agreement [Member] | StemoniX [Member] | Common Stock [Member]              
Business Acquisition [Line Items]              
Stock issued during the period for merger, shares 11,007,186            
Business combination fair value $ 50,740,000            
Merger Agreement [Member] | StemoniX [Member] | Common Stock Warrants [Member]              
Business Acquisition [Line Items]              
Stock issued during the period for merger, shares 2,157,686            
Business combination fair value $ 9,040,000.00            
Merger Agreement [Member] | StemoniX [Member] | Common Stock Options [Member]              
Business Acquisition [Line Items]              
Stock issued during the period for merger, shares 55,907,000            
Business combination fair value $ 139,000            
Merger Agreement [Member] | StemoniX [Member] | Holders [Member]              
Business Acquisition [Line Items]              
Stock issued during the period for merger, shares   17,977,544          
Common Stock, Par or Stated Value Per Share   $ 0.0001          
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award   891,780          
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit   $ 0.66          
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit   4.61          
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price   $ 1.46          
Merger Agreement [Member] | StemoniX [Member] | Investor [Member]              
Business Acquisition [Line Items]              
Warrants and Rights Outstanding, Maturity Date   Feb. 23, 2026          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   143,890         143,890
Shares Issued, Price Per Share   $ 5.9059         $ 5.9059
Merger Agreement [Member] | StemoniX and Cancer Genetics Inc [Member]              
Business Acquisition [Line Items]              
Business combination acquisition related costs     $ 2,145,000   $ 1,440,000    
Business combination accounts payable     63,000   $ 1,000,000.0    
Merger Agreement [Member] | StemoniX and Cancer Genetics Inc [Member] | Trade Names [Member]              
Business Acquisition [Line Items]              
Business combination intangible assets     $ 1,500,000        
Business combination useful life     10 years        
Merger Agreement [Member] | StemoniX and Cancer Genetics Inc [Member] | Customer Relationships [Member]              
Business Acquisition [Line Items]              
Business combination intangible assets     $ 8,000,000.0        
Business combination useful life     10 years        
Royalty payment percentage     1.00%        
Revenue percentage description     Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments.